TYK2 JH2 Pseudokinase Domain Inhibitor Screening Assay Kit

Catalog #
78107
$2,485 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The TYK2 JH2 Pseudokinase Domain Inhibitor Screening Assay Kit is designed for screening and profiling small molecules that displace the fluorescently labeled probe (JH2 probe 1) from the JH2 domain of TYK2. The assay is based on the competition of the test compound with the JH2 probe for binding to purified TYK2 JH2. Using this kit, only one simple step on a microplate is required for screening. The JH2 probe 1 is incubated with a sample containing TYK2 JH2 to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

Synonyms
IMD35 assay, JTK1 assay kit, tyrosine kinase 2 kit, Non-receptor tyrosine-protein kinase biochemical assay kit, JAK family
Product Info
Storage and Usage
Citations
Assay Kit Format
Fluorescence Polarization
Species
Human
Supplied As
This kit comes in a convenient 384-well format, with enough recombinant human TYK2 JH2 and fluorescently labeled ATP binding site tracer (JH2 probe 1) for 384 reactions.
Materials Required But Not Supplied

Adjustable micropipettor and sterile tips
Microplate reader capable of reading fluorescence polarization

Format
Catalog Component Amount Storage
100523 TYK2 (JH2 Domain) 60 µg -80°C Avoid 
multiple
freeze/
thaw 
cycles!
78103 JH2 Probe 1, 10 μM (Protect from light) 10 µl -80°C
78106 JH2 Binding Buffer 25 ml -20°C
  384-well black microplate 1 Room
Temp
 
UniProt #
P29597
Background

Janus kinases (JAKs) are a family of intracellular nonreceptor tyrosine kinases including Jak1, Jak2, Jak3 and TYK2, that has been recognized as an important modulator in inflammatory processes. JAKs contain a catalytically inactive pseudokinase regulatory domain (JH2) as well as an active kinase domain (JH1). Selective inhibition of one specific Jak is a challenging task since the enzymes sharehigh homology in the active site of JH1. Recent reports demonstrate that the pseudokinase domain (JH2) could provide an ideal allosteric site for selective inhibitor development.

References

Wrobleski, S. T., et al. J. Med. Chem. 2019, 62(20): 8973-8995.